您好,欢迎您

【2018 ASCO】中国好声音之中国医学科学院肿瘤医院内科

2018年04月28日
整理:肿瘤资讯
来源:肿瘤资讯

2018 ASCO大会即将到来!今年的ASCO会议上, 中国医学科学院肿瘤医院内科共有13篇研究入选,徐兵河教授的关于难治性转移性乳腺癌的研究和依荷芭丽·迟教授关于转移性软组织肉瘤的研究将在ASCO大会上口头发言。下面快跟随小编来看看吧!

Oral Session

徐兵河教授.jpg

徐兵河 教授(第二次ASCO大会口头发言)

中国医学科学院肿瘤医院

  • 标题:Phase III multicenter, randomized study of utidelone plus capecitabine versus capecitabine alone for heavily pretreated, anthracycline- and taxane-refractory metastatic breast cancer.

  • 时间:6月3日 9:00 AM-9:12 AM

  • 地点:Hall D2

微信图片_20180428161356.jpg

依荷芭丽·迟 教授(第二次ASCO大会口头发言)中国医学科学院肿瘤医院

  • 标题:安罗替尼治疗转移性软组织肉瘤: 随机、双盲、安慰剂对照多中心临床试验

  • 时间:6月4号 9:00 AM - 9:12 AM

  • 地点:S100a

Poster Board

徐兵河

题目:An open-label, multicenter, phase Ib study to evaluate RC48-ADC in patients with HER2-positive metastatic breast cancer.

王佳玉

题目:An open-label, dose-escalation phase I study to evaluate RC48-ADC, a novel antibody-drug conjugate, in patients with HER2-positive metastatic breast cancer.

段建春

题目:Theoretical model and clinical validation of blood tumor mutation burden (bTMB) detection for cancer immunotherapy.

王文娜

题目:Correlation of peripheral T cell receptor repertoire with response to neoadjuvant chemotherapy plus trastuzumab in early-stage HER2-positive breast cancer.

杨晟

题目:Effect of JS001, a monoclonal antibody targeting programed death-1(PD-1), on responses and disease control in patients with advanced or refractory alveolar soft part sarcoma: Results from a phase 1 trial.

宋岩

题目:Vorolanib (CM082) in Chinese patients with advanced solid tumor: A phase 1, open-label, dose escalation study.

王志杰

题目:Co-mutations of DNA damage response system as predictive biomarker for immune checkpoint blockades.

石远凯

题目:Sintilimab (IBI308) in relapsed/refractory classical Hodgkin lymphoma: A multicenter, single-arm phase 2 trial in China (ORIENT-1 study).

易宗毕

题目:Impact of HER2 mutation status on personalized molecular targeted therapy in advanced breast cancers.

林少妍

题目:Polymorphisms of MTHFR and TYMS to predict capecitabineinduced hand-foot syndrome in patients with metastatic breast cancer.

马飞

题目:Mutation signature of patients with ER+ metastatic breast cancer who received endocrine therapy.

孙燕

题目:A multicenter, single arm phase II trial of a small molecule immunemodulator icaritin: Safety, overall survival, immune dynamics, and PD-L1 expression in advanced hepatocellular carcinoma.

以上如有遗漏,请给我们留言!!!


责任编辑:肿瘤资讯-贾老师

相关阅读